Clozic

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Clozic 表现出可逆的抗增殖作用，可用于作为潜在抗关节炎药物的研究。

Clozic exhibits reversible anti-proliferative effects and can be used in studies about serving as a potential anti-arthritic agent.(In Vitro):Clozic (>50 μM) dose-dependently decreases the amount of matrix protein synthesized by RHMC cell cultures. Clozic dose-dependently inhibits RHMC cell culture growth. Clozic (500 μM) does not affect Lactate dehydrogenase levels.

Clozic is a potential anti-arthritic agent. Concentrations of Clozic greater than 50 μM cause a dose-dependent decrease in the amount of matrix protein synthesized by RHMC cell cultures. Inhibition of RHMC cell culture growth by Clozic occurs in a dose-dependent manner. The anti-proliferative effect of Clozic on RHMC cell growth is reversible. Lactate dehydrogenase (LDH) levels in media taken from RHMC cell cultures exposed to 500 μM Clozic for 3 days do not significantly differ from LDH levels in control cell culture media.

——

ICI 55897 | Clobuzarit

Others

Other Targets

MTH1

——

——

22494-47-9

304.77

C17H17ClO3

>98% (HPLC)

——

CC(C)(OCc1ccc(cc1)-c1ccc(Cl)cc1)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years